← All companies
AMICUS THERAPEUTICS, INC.
FOLD - CIK 0001178879
Market cap$4.55 B
Rank#1468
SEC filings2,171
AMICUS THERAPEUTICS, INC. trades as FOLD and has a market capitalization of $4.55 B, making it the #1468 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $634.21M, up 20.0% from the prior year and net income of -$27.11M. This page tracks AMICUS THERAPEUTICS, INC. through 2,171 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$634.21MFY 2025
Net income (latest FY)-$27.11MFY 2025
Operating cash flow (latest FY)$33.15MFY 2025
Total assets (latest FY)$949.87MFY 2025
Gross margin88.5%latest FY
Net margin-4.3%latest FY
Financial performance
Over the last 9 fiscal years AMICUS THERAPEUTICS, INC.'s revenue grew from $4.96M to $634.21M, a compound annual growth rate of 71.4%. Net profit margin expanded from -4034.7% to -4.3% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $4.55 B
- Share price (derived)market cap / shares outstanding
- $14.49
- EPS (diluted)FY 2025
- $-0.09
- Shares outstandingas of 2026-02-12
- 0.31B
- Total equityas of 2025-12-31
- $274.24M
- Return on equity
- -9.9%
- Long-term debtas of 2025-12-31
- $392.66M
- Cash & equivalentsas of 2025-12-31
- $214.01M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-05-07 |
| SCHEDULE 13G | - | 2026-05-01 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
Recent press releases
- Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates2026-02-20
February 20, 2026 16:01 ET
- Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates2025-11-04
November 04, 2025 07:00 ET
- Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 20252025-10-23
October 23, 2025 07:00 ET
- New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM2025-09-08
September 08, 2025 09:00 ET
- Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates2025-07-31
July 31, 2025 07:00 ET
Similar companies
The largest companies sharing AMICUS THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is AMICUS THERAPEUTICS, INC.'s market cap?
AMICUS THERAPEUTICS, INC. (FOLD) has a market capitalization of $4.55 B as of 2026-06-11, ranking #1468 among US-listed companies.
How much revenue does AMICUS THERAPEUTICS, INC. make?
AMICUS THERAPEUTICS, INC. reported revenue of $634.21M for fiscal year 2025, an increase of 20.0% year over year.
Is AMICUS THERAPEUTICS, INC. profitable?
In its latest fiscal year AMICUS THERAPEUTICS, INC. reported a net loss of $27.11M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.